Edinburgh-based biotech startup Concinnity Genetics has efficiently closed an oversubscribed €3.6 million seed funding spherical.
The funding was led by Eos Advisory, with participation from Scottish Enterprise, Outdated Faculty Capital—the College of Edinburgh’s enterprise funding fund—and Maven Capital Companions.
This funding may also allow Concinnity to spin out from the lab of Professor Susan Rosser and the UKRI UK Centre for Mammalian Artificial Biology on the College of Edinburgh and set up operations in Scotland’s life science hub.
“We’re so excited to be taking the subsequent step in our spin-out journey and need to sincerely thank all of the buyers and supporters who’ve helped us make it occur. Our ambition is to be the go-to associate for gene management to make gene and cell therapies as secure as potential,” stated CEO Jessica Birt. “This dedication from our buyers, constructing on the continued assist from Scottish Enterprise, speaks to the potential they see in our work, and we look ahead to utilizing the funding to additional develop our know-how.”
Co-founded in 2023 by CEO Jessica Birt and CSO Dr Matthew Dale, Concinnity Genetics is a spinout from the College of Edinburgh. The corporate focuses on creating novel management mechanisms that permit exact regulation of gene therapies even after administration.
By integrating artificial biology with AI, their know-how permits gene therapies to regulate dynamically, probably decreasing uncomfortable side effects and enhancing therapeutic outcomes.
The funds are earmarked to provoke three new programmes creating ribonucleic acid (RNA)-based management programs focused at key purposes throughout the cell and gene remedy market, in addition to persevering with to develop Concinnity’s current management programs with the goal of acquiring vital information to provoke partnerships with prospects.
Andrew McNeill, Managing Companion at Eos Advisory, commented: “Concinnity is an ideal match for Eos’s concentrate on backing pioneering Scottish science, addressing a big unmet want in gene remedy. By combining artificial biology and AI-machine studying, the Concinnity know-how has been described because the ‘holy grail for rising gene therapies’, making such remedies each simpler and safer.”
Over the previous two years, Concinnity has been supported by Scottish Enterprise as a part of its Excessive Progress Spinout Programme. This funding has enabled the group to develop its know-how, producing information for industrial validation that has supported the profitable completion of this seed funding.
“This funding spherical clearly demonstrates the massive potential of Concinnity’s know-how, which has been recognised by buyers. Scottish Enterprise has supported the group since its beginnings throughout the College of Edinburgh, so it’s implausible to now be investing in it because it prepares to spin out,” stated Kerry Sharp, Director of Entrepreneurship and Funding at Scottish Enterprise. “Life sciences is one in every of Scotland’s key progress industries and our funding and ongoing enterprise assist will assist Concinnity convert and scale its innovation into worldwide progress, delivering most advantages for Scotland’s economic system.”
Concinnity Genetics represents an development within the area of gene remedy, with its AI-driven RNA management programs probably setting new requirements in remedy security and efficacy.
